MMP9 and hematocrit: Consequently, we conducted a comparative analysis of plasma levels of MMP-2 and MMP-9 within 24 hours of admission in our patient cohort to highlight any potential correlations with the risk of HT and adverse neurological outcomes at discharge and during the 90-day follow-up.